** Jefferies revises down health imaging firm Pro Medicus' PME.AX near-term growth forecasts, considering the stepped minimum nature of the Trinity contract
** Brokerage trims firm's cardiology contribution estimates, leading to implied market share increase to 14% in FY26, down 15% from previous estimates
** Despite these adjustments, brokerage maintains its A$250 price target and 'Hold' rating
** Stock down 9% YTD
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com; X: @thatstanishk;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。